Patient cohorts with the higher frequency of aggressive subtypes have shown higher rates of tumor take and stabilization and in most studies PDX mainly derived from aggressive subtypes, such as triple-negative, luminal B or HER2-positive subtypes. This evidence concerns the gene ERBB2 and neoplasm.